Pasithea Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel therapeutics for psychiatric and neurological disorders. Leveraging advances in psychedelic science and neuromodulation, Pasithea’s pipeline includes small- and large-molecule candidates designed to address unmet needs in conditions such as post-traumatic stress disorder (PTSD), major depressive disorder (MDD), and neurodegenerative diseases. The company’s research platform integrates medicinal chemistry with translational neuroscience, aiming to deliver therapies that provide rapid and durable symptom relief.
Founded in 2020 under the name Silo Pharma and rebranded as Pasithea Therapeutics in 2022, the company has established strategic collaborations with academic institutions and contract research organizations across North America and Europe. Pasithea’s preclinical and early clinical studies are supported by proprietary formulations intended to optimize pharmacokinetics and safety profiles. The company’s lead clinical programs include both monoamine receptor modulators and next-generation psychedelic analogs, reflecting its commitment to a diversified approach in CNS drug discovery.
Pasithea maintains operations in the United States and the United Kingdom, with research laboratories and regulatory teams situated to navigate evolving global guidelines for psychedelic-assisted therapies. Through partnerships with specialty chemistry providers and clinical trial sites, the company seeks to accelerate development timelines while meeting rigorous regulatory standards. Outreach initiatives also engage patient advocacy groups and scientific communities to foster dialogue on novel treatment modalities.
Under the leadership of Chief Executive Officer Federico A. Gomez, Pasithea Therapeutics’ management team brings extensive experience in neuropharmacology, clinical operations, and life sciences finance. The board of directors includes veterans of biotechnology and drug development, guiding strategic decisions from early-stage research through regulatory review. With a focus on scientific innovation and patient-centric outcomes, Pasithea aims to position itself at the forefront of next-generation mental health therapies.
AI Generated. May Contain Errors.
